Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Agios Pharmaceuticals (AGIO) on August 20, according to a September 10 disclosure. His other recent trades included purchases of Quanta Services, Eaton, Walmart, Goldman Sachs and Wheaton Precious Metals, alongside several stock sales.
• AGIO opened at $33.60, with a 12-month range of $22.24–$46.00 and a market capitalization of about $2.01 billion. Agios missed its latest quarterly EPS estimate, reporting a $1.69 loss per share, though revenue of $44.75 million exceeded expectations.
• Institutional ownership has increased, including a new $239.6 million BlackRock stake and major additions by California’s teachers’ retirement system and Wellington Management. Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $41.25.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on August 20th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 8/28/2026.
• Purchased $15,001 - $50,000 in shares of Quanta Services NYSE: PWR on 8/27/2026.
• Purchased $15,001 - $50,000 in shares of Eaton NYSE: ETN on 8/27/2026.
• Sold $15,001 - $50,000 in shares of NIKE NYSE: NKE on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Wheaton Precious Metals NYSE: WPM on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Walmart NASDAQ: WMT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 8/26/2026.
• Sold $15,001 - $50,000 in shares of Lamar Advertising NASDAQ: LAMR on 8/25/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/25/2026.

Agios Pharmaceuticals Stock Performance

AGIO opened at $33.60 on Friday. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00. The firm has a market cap of $2.01 billion, a PE ratio of -4.79 and a beta of 0.60. The firm's fifty day moving average is $35.26 and its two-hundred day moving average is $32.03.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Equities analysts forecast that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of AGIO. BlackRock Inc. bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth $239,582,000. California State Teachers Retirement System grew its position in Agios Pharmaceuticals by 3,515.3% in the second quarter. California State Teachers Retirement System now owns 2,478,800 shares of the biopharmaceutical company's stock worth $91,988,000 after acquiring an additional 2,410,236 shares in the last quarter. Wellington Management Group LLP increased its stake in Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock valued at $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. MPM Bioimpact LLC bought a new position in Agios Pharmaceuticals in the fourth quarter valued at $35,478,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Agios Pharmaceuticals during the second quarter valued at about $47,800,000.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of the company's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Bank of America upped their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 7th. HC Wainwright lifted their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Royal Bank Of Canada upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a "sector perform" rating in a report on Tuesday, July 7th. Finally, TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $41.25.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.